E.J. Lawitz

738 total citations
27 papers, 409 citations indexed

About

E.J. Lawitz is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, E.J. Lawitz has authored 27 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hepatology, 9 papers in Epidemiology and 6 papers in Infectious Diseases. Recurrent topics in E.J. Lawitz's work include Hepatitis C virus research (17 papers), Systemic Lupus Erythematosus Research (6 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). E.J. Lawitz is often cited by papers focused on Hepatitis C virus research (17 papers), Systemic Lupus Erythematosus Research (6 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). E.J. Lawitz collaborates with scholars based in United States, France and Spain. E.J. Lawitz's co-authors include M. Rodríguez‐Torres, Graham R. Foster, Pietro Andreoné, Stefan Zeuzem, Gastón Picchio, Stanislas Pol, Roberto Focaccia, Paul J. Pockros, Zobair M. Younossi and John G. McHutchison and has published in prestigious journals such as Gastroenterology, Journal of Hepatology and Digestive and Liver Disease.

In The Last Decade

E.J. Lawitz

27 papers receiving 390 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E.J. Lawitz United States 12 393 371 93 37 15 27 409
J. McHutchison United States 11 315 0.8× 290 0.8× 81 0.9× 31 0.8× 19 1.3× 42 341
Isabelle Lonjon‐Domanec France 14 541 1.4× 522 1.4× 79 0.8× 48 1.3× 35 2.3× 37 596
J. Albrecht United States 10 391 1.0× 368 1.0× 64 0.7× 54 1.5× 33 2.2× 18 449
E Ibrányi Hungary 5 366 0.9× 339 0.9× 40 0.4× 41 1.1× 14 0.9× 13 386
Eiji Tanaka Japan 7 292 0.7× 279 0.8× 41 0.4× 37 1.0× 13 0.9× 8 361
S Mauss Germany 7 245 0.6× 216 0.6× 60 0.6× 30 0.8× 30 2.0× 17 300
Zayani Sims United States 7 373 0.9× 332 0.9× 69 0.7× 47 1.3× 24 1.6× 10 401
Eirum Chaudhri Japan 3 509 1.3× 437 1.2× 113 1.2× 60 1.6× 26 1.7× 3 531
Ahmed El Ray Egypt 6 330 0.8× 308 0.8× 28 0.3× 55 1.5× 5 0.3× 19 356
A.C. Cardoso France 4 445 1.1× 475 1.3× 28 0.3× 26 0.7× 18 1.2× 8 503

Countries citing papers authored by E.J. Lawitz

Since Specialization
Citations

This map shows the geographic impact of E.J. Lawitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.J. Lawitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.J. Lawitz more than expected).

Fields of papers citing papers by E.J. Lawitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.J. Lawitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.J. Lawitz. The network helps show where E.J. Lawitz may publish in the future.

Co-authorship network of co-authors of E.J. Lawitz

This figure shows the co-authorship network connecting the top 25 collaborators of E.J. Lawitz. A scholar is included among the top collaborators of E.J. Lawitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.J. Lawitz. E.J. Lawitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lawitz, E.J., Kris V. Kowdley, Stuart C. Gordon, et al.. (2025). Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for up to 3 Years From the ASSURE Study. Digestive and Liver Disease. 57(12 Suppl 12). S88–S89. 1 indexed citations
2.
3.
Guedj, Jérémie, et al.. (2013). 1196 ANALYSIS OF THE KINETICS OF VIRAL DECLINE DURING 14 DAYS OF ADMINISTRATION OF SOFOSBUVIR AND GS-0938. Journal of Hepatology. 58. S486–S487. 1 indexed citations
4.
Dvory‐Sobol, Hadas, Evguenia S. Svarovskaia, Viktoria Gontcharova, et al.. (2013). 1193 RESISTANCE ANALYSES USING DEEP AND POPULATION SEQUENCING AFTER 3 DAY MONOTHERAPY WITH GS-9669, A NOVEL NON-NUCLEOSIDE NS5B INHIBITOR IN GENOTYPE 1 HCV PATIENTS. Journal of Hepatology. 58. S485–S485. 4 indexed citations
5.
6.
Lawitz, E.J., Jacqueline Hill, Lydie Hazan, et al.. (2012). 1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS. Journal of Hepatology. 56. S470–S471. 7 indexed citations
7.
8.
Andreoné, Pietro, Stanislas Pol, Stuart K. Roberts, et al.. (2012). T-27 Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study. Digestive and Liver Disease. 44. S23–S23. 14 indexed citations
9.
Bronowicki, J.-P., Mitchell Davis, S. Flamm, et al.. (2012). 11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS. Journal of Hepatology. 56. S6–S6. 31 indexed citations
10.
11.
12.
Foster, Graham R., Stefan Zeuzem, Pietro Andreoné, et al.. (2011). 6 SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION. Journal of Hepatology. 54. S3–S4. 21 indexed citations
13.
14.
15.
16.
McHutchison, John G., Gregory T. Everson, Ira M. Jacobson, et al.. (2010). 277 GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN IMPROVES BIOPSY NECRO-INFLAMMATORY SCORES AND ALT NORMALIZATION AT 48 WEEKS VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV PATIENTS. Journal of Hepatology. 52. S116–S116. 3 indexed citations
17.
Lawitz, E.J., Bradley Vince, Nicole Grunenberg, et al.. (2010). 2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256. Journal of Hepatology. 52. S466–S467. 10 indexed citations
18.
19.
Lawitz, E.J., Thomas Boyer, Gregory T. Everson, et al.. (2009). 627 GI-5005 IMMUNOTHERAPY PLUS PEG-IFN/RIBAVIRIN VERSUS PEG-IFN/RIBAVIRIN IN GENOTYPE 1 CHRONIC HCV SUBJECTS; PRELIMINARY PHASE 2 EVR ANALYSES. Journal of Hepatology. 50. S230–S231. 4 indexed citations
20.
Lawitz, E.J., M. Rodríguez‐Torres, Andrew J. Muir, et al.. (2006). 28 Days of the Hepatitis C Protease Inhibitor VX-950, in Combination With PEG-Interferon-ALFA-2a and Ribavirin, Is Well-Tolerated and Demonstrates Robust Antiviral Effects. Gastroenterology. 131(3). 950–951. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. McHutchison Breakdown of academic impact, for papers by Isabelle Lonjon‐Domanec Breakdown of academic impact, for papers by J. Albrecht Breakdown of academic impact, for papers by E Ibrányi Breakdown of academic impact, for papers by Eiji Tanaka Breakdown of academic impact, for papers by S Mauss Breakdown of academic impact, for papers by Zayani Sims Breakdown of academic impact, for papers by Eirum Chaudhri Breakdown of academic impact, for papers by Ahmed El Ray Breakdown of academic impact, for papers by A.C. Cardoso
Rankless by CCL
2026